

MORRISTOWN CARDIOLOGY ASSOCIATES
DIVISION OF NUCLEAR MEDICINE
182 SOUTH STREET
MORRISTOWN, NJ 07960

NMS82

Licensing Assistant Section
Nuclear Materials Safety Branch
U.S. Nuclear Regulatory Commission, Region I
475 Allendale Road
King of Prussia, PA 19406-1415

03032676

Re: RSO amendment NRC License # 29-28734-01

July 22, 2007

Dear Sir/Madam:


Please amend our license to change the RSO from Richard Watson, M.D. Jeffrey G. Schwartz M.D. Preceptorship form 313A signed by Richard Watson, M.D., authorized user/RSO, on NRC license #29-28734 is enclosed.

Please contact our Physics Consultant, Elaine Rovazzi, M.S. @ (973) 322-5118 for any further information.

Sincerely,



Richard Watson, M.D.
Management / RSO



Jeffrey G. Schwartz, M.D.
Authorized user

RECEIVED
REGION I

2007 AUG 27 AM 10:36

Enc. NRC Preceptorship form 313A (AUD)
NRC License # 29-28734-01

140982

MEDICAL USE TRAINING AND EXPERIENCE AND PRECEPTOR ATTESTATION (continued)

10. SUPERVISING INDIVIDUAL - IDENTIFICATION AND QUALIFICATIONS

The training and experience indicated above was obtained under the supervision of (if more than one supervising individual is needed to meet requirements in 10 CFR Part 35, provide the following information for each) :

A. Name of Supervisor

B. Supervisor is:

Richard I. Watson M.D.

Authorized User

Authorized Medical Physicist

Radiation Safety Officer

Authorized Nuclear Pharmacist

C. Supervisor meets requirements of Part 35, Section(s)

for medical uses in Part 35, Section(s) 35.200 Cardiovascular Imaging

D. Address Morristown Cardiology Associates
182 South Street
Morristown NJ 07960

E. Materials License Number

29-28734-01

PART II - PRECEPTOR ATTESTATION

Note: This part must be completed by the individual's preceptor. If more than one preceptor is necessary to document experience, obtain a separate preceptor statement from each. This part is not required to meet training requirements in 35.590 or Part 35, Subpart J (except 35.980).

I attest the individual named in Item 1: Jeffery G. Schwartz M.D.

11a.

has satisfactorily completed the requirements in Part 35, Section(s) and Paragraph(s) 290.01(ii)(6) as documented in section(s) _____ of this form.

11b. Select one

meets the requirements in 35.50(e) 35.51(c) 35.390(b)(1)(ii)(G) 35.690(c) for _____ types of use, as documented in section(s) _____ of this form.

N/A

11c.

has achieved a level of competency sufficient to independently operate a nuclear pharmacy (for 35.980); **OR**

has achieved a level of competency sufficient to function independently as an authorized USER for 35.200 uses (or units); **OR**

has achieved a level of radiation safety knowledge sufficient to function CARD. ONLY independently as a Radiation Safety Officer for a medical use licensee; **OR**

N/A

11d.

I am an Authorized Nuclear Pharmacist; **OR** I am a Radiation Safety Officer; **OR**

I meet the requirements of 35.57 section(s) of 10 CFR Part 35

or equivalent Agreement State requirements to be a preceptor AU or AMP

for the following byproduct material uses (or units): 35.200 CARD. ONLY

A. Address

Morristown Cardiology Associates
182 South Street
Morristown NJ 07960

B. Materials License Number

29-28734-01

C. NAME OF PRECEPTOR (print clearly)

Richard I. Watson M.D.

D. SIGNATURE - PRECEPTOR

Richard Watson MD

E. DATE

8-22-7

NRC FORM 313A (AUI)
(10-2006)

U.S. NUCLEAR REGULATORY COMMISSION

**AUTHORIZED USER TRAINING AND EXPERIENCE
AND PRECEPTOR ATTESTATION**
(for uses defined under 35.100, 35.200, and 35.500)
[10 CFR 35.190, 35.290, and 35.590]

APPROVED BY OMB: NO. 3150-0120
EXPIRES: 10/31/2008

Name of Proposed Authorized User

State or Territory Where Licensed

Jeffrey G. Schwartz MD

New Jersey

Requested Authorization(s) (check all that apply)

35.100 Uptake, dilution, and excretion studies

35.200 Imaging and localization studies *Cardiovascular Imaging*

35.500 Sealed sources for diagnosis (specify device _____)

PART I - TRAINING AND EXPERIENCE
(Select one of the three methods below)

* Training and Experience, including board certification, must have been obtained within the 7 years preceding the date of application or the individual must have obtained related continuing education and experience since the required training and experience was completed. Provide dates, duration, and description of continuing education and experience related to the uses checked above.

1. Board Certification

a. Provide a copy of the board certification.

b. If using only 35.500 materials, stop here. If using 35.100 and 35.200 materials, skip to and complete Part II Preceptor Attestation.

2. Current 35.390 Authorized User Seeking Additional 35.290 Authorization

a. Authorized user on Materials License _____ meeting 10 CFR 35.390 or equivalent Agreement State requirements seeking authorization for 35.290.

b. Supervised Work Experience.
(If more than one supervising individual is necessary to document supervised work experience, provide multiple copies of this section.)

Description of Experience	Location of Experience/License or Permit Number of Facility	Clock Hours	Dates of Experience*
Eluting generator systems appropriate for the preparation of radioactive drugs for imaging and localization studies, measuring and testing the eluate for radionuclidic purity, and processing the eluate with reagent kits to prepare labeled radioactive drugs			

Total Hours of Experience:

Supervising Individual

License/Permit Number listing supervising individual as an authorized user

Supervisor meets the requirements below, or equivalent Agreement State requirements (check all that apply).

35.290

35.390 + generator experience in 32.290(c)(1)(ii)(G)

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p>Licensee</p> <p>1. Morristown Cardiology Associates, P.A.</p> <p>2. 182 South Street Morristown, New Jersey 07960</p>	<p>In accordance with the letter dated January 22, 2007,</p> <p>3. License number 29-28734-01 is amended in its entirety to read as follows:</p> <hr/> <p>4. Expiration date May 31, 2012</p> <p>5. Docket No. 030-32676 Reference No.</p>
--	--

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material identified in 10 CFR 35.100</p> <p>B. Any byproduct material identified in 10 CFR 35.200</p>	<p>7. Chemical and/or physical form</p> <p>A. Any radiopharmaceutical identified in 10 CFR 35.100</p> <p>B. Any radiopharmaceutical identified in 10 CFR 35.200 except generators and gas</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As needed</p> <p>B. As needed</p>
--	---	---

9. Authorized use:
- A. Any cardiac uptake, dilution and excretion procedure approved in 10 CFR 35.100.
 - B. Any cardiac imaging and localization procedure approved in 10 CFR 35.200.

CONDITIONS

- 10. Licensed material may be used only at the licensee's facilities located at 182 South Street, Morristown, New Jersey.
- 11. The Radiation Safety Officer for this license is Richard I. Watson, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for the materials and uses indicated:

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
29-28734-01

Docket or Reference Number
030-32676

Amendment No. 4


<u>Authorized Users</u>	<u>Material and Use</u>
Richard I. Watson, M.D.	35.100; 35.200
Karel Raska, M.D.	35.100; 35.200
Allen Hsieh, M.D.	35.100; 35.200
Jeffrey G. Schwartz, M.D.	35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing financial assurance for decommissioning.
14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."
15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated January 30, 1992 [ML070600217]
 B. Letter dated April 22, 1992 [ML070600234]
 C. Letter dated March 9, 2002 [ML021000147]

For the U.S. Nuclear Regulatory Commission

Date March 14, 2007

By



Dennis R. Lawyer
 Commercial and R&D Branch
 Division of Nuclear Materials Safety
 Region I
 King of Prussia, Pennsylvania 19406

Wednesday, March 14, 2007 6:20:40 AM

This is to acknowledge the receipt of your letter/application dated

7/22/2007 ^(RECEIVED) ~~8/27/2007~~ and to inform you that the initial processing which includes an administrative review has been performed.

Amend. 29-28734-01
There were no administrative omissions. Your application was assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information.

Please provide to this office within 30 days of your receipt of this card

A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 140982.
When calling to inquire about this action, please refer to this control number.
You may call us on (610) 337-5398, or 337-5260.